Asparaginase

Antineoplastic agent Enzyme (L-asparagine amidohydrolase)

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog SC, IM, or IV 10,000 IU/m² Once weekly or as part of induction protocols (e.g., 3 times weekly for 2-3 weeks) Duration: Typically 2-4 weeks in induction; may be used in maintenance protocols
Notes: Administer as a slow IV infusion or SC injection. Premedicate with antihistamines or corticosteroids to reduce risk of hypersensitivity reactions.
Cat SC, IM, or IV 10,000 IU/m² Once weekly or as part of induction protocols Duration: Typically 2-4 weeks in induction
Notes: Monitor for hypersensitivity reactions; cats may be more sensitive to anaphylaxis.
Horse IV 10,000 IU/m² Once weekly Duration: As part of chemotherapy protocol
Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications
  • Antineoplastic agent for lymphoid malignancies
Dog (Canine)
  • Treatment of lymphosarcoma (lymphoma) as part of combination chemotherapy protocols
  • Treatment of acute lymphoblastic leukemia (ALL)
Cat (Feline)
  • Treatment of lymphosarcoma (lymphoma) as part of combination chemotherapy protocols
  • Treatment of acute lymphoblastic leukemia (ALL)

Pharmacology & Mechanism of Action

Drug Class: Antineoplastic agent | Pharmacological Group: Enzyme (L-asparagine amidohydrolase)

Mechanism of Action: Asparaginase catalyzes the hydrolysis of L-asparagine to L-aspartic acid and ammonia. Many neoplastic cells, particularly lymphoblasts, lack or have low expression of asparagine synthetase and are dependent on exogenous asparagine for survival. By depleting circulating asparagine, asparaginase selectively kills these cells. Normal cells can synthesize asparagine and are less affected.

Pharmacodynamics: Asparaginase produces a rapid and profound decrease in plasma asparagine levels. The antineoplastic effect is schedule-dependent, with prolonged exposure being more effective. It is cell-cycle specific for the S phase and is most effective against rapidly dividing cells. It also has immunosuppressive properties due to inhibition of lymphocyte proliferation.

⚡ Pharmacokinetics Summary

Absorption: Asparaginase is not absorbed orally and must be administered parenterally (IM, IV, or SC).
Distribution: Distribution is primarily intravascular due to its large molecular weight. It penetrates poorly into cerebrospinal fluid (CSF) unless the meninges are inflamed.
Metabolism: Metabolized by the reticuloendothelial system and proteolytic enzymes. No significant hepatic metabolism.
Excretion: Excreted via the reticuloendothelial system; not significantly excreted in urine or bile.
Half-Life: Dogs: 1.1-1.7 days; Cats: 1.2-1.5 days; Humans: 1-2 days.
Bioavailability: Not orally bioavailable; 100% bioavailable after IV administration.
Protein Binding: Minimal protein binding.

Available Formulations & Strengths

Injectable Solution (lyophilized powder for reconstitution) 10,000 IU/vial (IV, IM, SC)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to asparaginase
  • History of severe pancreatitis
  • Pregnancy (teratogenic potential)
  • Severe hepatic impairment (use with caution)
Warnings & Clinical Precautions:
  • Hypersensitivity reactions (including anaphylaxis) can occur; have epinephrine and antihistamines available.
  • Monitor for pancreatitis (especially in dogs) - check serum amylase and lipase.
  • May cause coagulopathy due to decreased protein synthesis; monitor clotting times.
  • Use with caution in patients with pre-existing hepatic or renal disease.
  • Immunosuppression may increase risk of infections.
  • Do not administer to animals with active infections.
  • Handle with care; avoid skin contact (wear gloves).

Adverse Effects & Reactions

Common:

  • Hypersensitivity reactions (urticaria, facial edema, vomiting)
  • Anorexia
  • Lethargy
  • Nausea/vomiting
  • Fever

Serious / Severe:

  • Anaphylaxis
  • Pancreatitis (potentially fatal)
  • Coagulopathy (bleeding disorders)
  • Hepatotoxicity (elevated liver enzymes)
  • Hyperglycemia (due to decreased insulin synthesis)
  • Neurotoxicity (rare)

Rare:

  • Renal toxicity
  • Bone marrow suppression (mild)
  • Allergic reactions to E. coli-derived product (switch to Erwinia-derived if available)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Methotrexate Asparaginase may decrease methotrexate's antitumor effect if given concurrently; administer asparaginase after methotrexate to avoid antagonism. Moderate
Vincristine May increase neurotoxicity and risk of peripheral neuropathy when used together. Moderate
Corticosteroids (e.g., prednisone) May increase risk of hyperglycemia and immunosuppression. Mild
Other hepatotoxic drugs Additive hepatotoxicity. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe hypersensitivity reactions
  • Pancreatitis
  • Coagulopathy
  • Hepatic dysfunction
  • Neurological signs (seizures, coma)

Emergency Treatment Protocol: There is no specific antidote. Treatment is supportive: discontinue drug, manage anaphylaxis with epinephrine, IV fluids, antihistamines, corticosteroids. Monitor pancreatic and liver enzymes, coagulation parameters. Provide intensive supportive care.

Food Animal Withdrawal Times

Not approved for food animals; no withdrawal times established. Use in food animals is prohibited or extra-label with extended withdrawal periods.

Storage, Handling & Regulatory Information

Storage Temperature: Store lyophilized powder at 2-8°C (refrigerated). Reconstituted solution is stable for 8 hours at room temperature or 48 hours if refrigerated.

Handling & Special Conditions: Protect from freezing. Do not shake vigorously.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not specifically approved for veterinary use, but used extra-label in veterinary oncology.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is prohibited under AMDUCA due to lack of withdrawal times and potential residues. In companion animals, extra-label use is common in oncology.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Asparaginase is a key component in the treatment of lymphoma and lymphoblastic leukemia in dogs and cats. It is often used in induction protocols (e.g., CHOP-based) to achieve rapid remission. Because of the high risk of hypersensitivity reactions, especially with repeated administration, premedication with diphenhydramine and dexamethasone is recommended. Monitor for pancreatitis, which can be severe and life-threatening. If the patient develops a hypersensitivity reaction to E. coli-derived asparaginase, Erwinia-derived asparaginase may be used as an alternative. Always handle with care due to its cytotoxic nature.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)